Transcode Therapeutics Inc (RNAZ) Stock Analysis

Transcode Therapeutics Inc (RNAZ) is a publicly traded company in the HEALTHCARE sector. It trades at $5.30, carries a market capitalization of $4.88M. This page summarizes the public market data, fundamentals, and frequently asked questions for RNAZ, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Transcode Therapeutics Inc currently has a Neutral sentiment score of -0.03.

About Transcode Therapeutics Inc

TransCode Therapeutics, Inc. (RNAZ) is an innovative biopharmaceutical company focused on advancing the treatment of metastatic diseases through the development and commercialization of novel therapeutic agents. Headquartered in Boston, Massachusetts, TransCode is leveraging its proprietary technologies to address significant unmet medical needs in oncology, with an emphasis on enhancing the effectiveness of cancer treatments. The company's commitment to transforming cancer care positions it ...

GNG Research Analysis

GNG Research scores Transcode Therapeutics Inc (RNAZ) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RNAZ.

Frequently Asked Questions

Does RNAZ pay dividends?

Transcode Therapeutics Inc (RNAZ) does not currently pay a regular dividend.

What is RNAZ's market cap?

Transcode Therapeutics Inc (RNAZ) has a market capitalization of $4.88M with a current stock price of $5.30.